Evidence map›Paper›PMID 42028577›Full record

ArticleMolecular therapy. Nucleic acids2026

Engineered mRNA backbones for gene expression in human T cells.

Gilad Gibor, Neve Tzvi, Amilia Meir, Hiba Abu-Hariri, Anat Shemer, Shai Kilim, Sophie Abelian, Ortal Harush, Orit Itzhaki, Ronnie Shapira-Frommer and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Nucleic acids, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Gilad GiborElla Lemelbaum Institute for Immuno-oncology, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.
Neve TzviElla Lemelbaum Institute for Immuno-oncology, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.
Amilia MeirCell Therapy Lab, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.
Hiba Abu-HaririImmunotherapy and Genetic Engineering, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.
Anat ShemerImmunotherapy and Genetic Engineering, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.
Shai KilimElla Lemelbaum Institute for Immuno-oncology, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.
Sophie AbelianUniversity Collage London, London, UK.
Ortal HarushElla Lemelbaum Institute for Immuno-oncology, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.
Orit ItzhakiElla Lemelbaum Institute for Immuno-oncology, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.
Ronnie Shapira-FrommerElla Lemelbaum Institute for Immuno-oncology, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.
Elad JacobyCell Therapy Lab, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.
Gal CafriImmunotherapy and Genetic Engineering, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.
Yochai WolfElla Lemelbaum Institute for Immuno-oncology, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Current mRNA approaches in immuno-oncology lack specificity for optimal T cell mRNA expression, necessitating tailored mRNA expression systems. In this study, we developed novel mRNA constructs in which the standard α-globin (HBA1) 5' UTR is replaced with sequences derived from genes highly expressed in effector T cells. Using primary human T cells, expression levels of UTR-modified reporter genes were evaluated, revealing significant variability based on the substituted UTR. For instance, interferon gamma (IFN-γ) UTRs facilitated enhanced and sustained protein expression, whereas TNF UTRs showed diminished expression. Unexpectedly, the

Indexed as

CAR-TimmunotherapymRNAMT: Oligonucleotides: Therapies and ApplicationsT cell biologyT cell engineeringTIGITUTR

Identifiers

PMID42028577
PMCPMC13101584

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.